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Abstract
Heavy cannabis abuse increases the risk of developing schizophrenia. Adolescents appear particularly
vulnerable to the development of psychosis-like symptoms after cannabis use. To test whether the
schizophrenia candidate gene neuregulin 1 (NRG1) modulates the effects of cannabinoids in adolescence,
we tested male adolescent heterozygous transmembrane domain Nrg1 mutant (Nrg1 TM HET) mice and
wild type-like littermates (WT) for their neurobehavioural response to repeated D9-tetrahydrocannabinol
(THC, 10 mg/kg i.p. for 21 d starting on post-natal day 31). During treatment and 48 h after treatment
withdrawal, we assessed several behavioural parameters relevant to schizophrenia. After behavioural
testing we measured autoradiographic CB1, 5-HT2A and NMDA receptor binding. The hyperlocomotor
phenotype typical of Nrg1 mutants emerged after drug withdrawal and was more pronounced in vehicle
than THC-treated Nrg1 TM HET mice. All mice were equally sensitive to THC-induced suppression of
locomotion. However, mutant mice appeared protected against inhibiting effects of repeated THC on
investigative social behaviours. Neither THC nor Nrg1 genotype altered prepulse inhibition. Repeated
adolescent THC promoted differential effects on CB1 and 5-HT2A receptor binding in the substantia nigra
and insular cortex respectively, decreasing binding in WT while increasing it in Nrg1 TM HET mice. THC
also selectively affected 5-HT2A receptor binding in several other regions in WT mice, whereas NMDA
receptor binding was only affected in mutant mice. Overall,Nrg1mutation does not appear to increase the
induction of psychotomimetic symptoms by repeated adolescent THC exposure but may attenuate some
of its actions on social behaviour and schizophrenia-relevant neurotransmitter receptor profiles.
Received 22 July 2011 ; Reviewed 5 September 2011 ; Revised 7 October 2011 ; Accepted 20 November 2011 ;
First published online 9 January 2012
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Introduction
The ‘two-hit ’ hypothesis of schizophrenia suggests
that genetic and environmental risk factors interact to
produce the disorder (Bayer et al. 1999). Onset of
symptoms is usually during adolescence or early
adulthood, periods of major change in brain mor-
phology and neural connectivity and thus increased
vulnerability to insult (Paus et al. 2008). Perturbation to
normal brain maturation during the transition from
adolescence to adulthood, for example, by drug abuse,
might contribute to exacerbation or precipitation of
schizophrenia onset. Cannabis abuse is linked with a
moderate increase in the risk of developing schizo-
phrenia (Moore et al. 2007). Interestingly, individuals
predisposed to schizophrenia are more vulnerable
to adverse effects of cannabis (i.e. hallucinations,
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confusion and learning and memory deficits ; d’Souza
et al. 2005; Peters et al. 2009). One mediator of this in-
creased vulnerability appears to be the schizophrenia
candidate gene catechol-O-methyltransferase (Caspi
et al. 2005). Further research has to clarify whether
other candidate genes have similar properties.
Neuregulin 1 (NRG1) is a proposed schizophrenia
susceptibility gene (Stefansson et al. 2002; for review
and meta-analysis respectively, see Harrison & Law,
2006; Munafo et al. 2006; but also see Sanders et al.
2008). One of several transgenic mouse models avail-
able for Nrg1 (Duffy et al. 2008) contains a hetero-
zygous mutation in the transmembrane domain (Nrg1
TM HET). Nrg1 TM HET mice show face and partial
predictive validity for schizophrenia, exhibiting age-
dependent locomotor and exploratory hyperactivity
(Karl et al. 2007; onset at age 5 months ; reversible
by clozapine treatment ; Stefansson et al. 2002) and
impaired preference for social novelty (O’Tuathaigh
et al. 2007). We have shown that male Nrg1 TM HET
mice possess increased sensitivity to neurobehaviour-
al effects of acute D9-tetrahydrocannabinol [THC; i.e.
enhancement of prepulse inhibition (PPI), hypoloco-
motive and anxiogenic effects, selective increases
in c-Fos expression; Boucher et al. 2007a, b]. This
phenomenon is sex-specific, since female Nrg1 TM
HET mice do not show increased behavioural sensi-
tivity to acute THC treatment (Long et al. 2010a). The
role of Nrg1 in the response to cannabinoid agonists is
further exemplified by altered rates of tolerance in
adult Nrg1 TM HET mice to the locomotor and anxio-
genic effects of the synthetic cannabinoid CP 55 940
(Boucher et al. 2011). Based on our findings, Nrg1
might be another genetic mediator of increased vul-
nerability to cannabis-induced psychosis.
Importantly, earlier age of onset of cannabis use
appears to confer increased susceptibility to detri-
mental effects in adulthood, such as cognitive deficits
(Ehrenreich et al. 1999; Pope et al. 2003), and may also
precipitate earlier onset of schizophrenia (Large et al.
2011). Rodent studies also suggest that cognitive defi-
cits are induced by chronic THC exposure during
adolescence, but not adulthood (Quinn et al. 2008;
Rubino et al. 2009a, b). Such early cannabinoid ex-
posure may have long-lasting behavioural and neuro-
biological consequences (Realini et al. 2009) and there
is evidence that both genetic and age-associated fac-
tors might play a role in the link between cannabis use
and psychosis. Therefore, we aimed to determine the
effects of acute and chronic adolescent THC on be-
haviour and receptor binding density in the Nrg1 TM
HET mouse. As these mice exhibit an age-dependent
phenotype, we hypothesized that male adolescent
Nrg1 TM HET mice, like adults (Boucher et al. 2007a),
would be more sensitive to the behavioural effects of
THC in a battery of tests relevant to schizophrenia,
resulting in earlier onset of schizophrenia-relevant
behaviours and a more severe phenotype. We ex-
pected that these behavioural changes would be ac-
companied by alterations in CB1, 5-HT2A and NMDA
receptors (NMDARs). These receptors are relevant
to the pharmacological effects of cannabis and the
pathophysiology of schizophrenia (Dalton et al. 2011;
Kang et al. 2009; Matsumoto et al. 2005; Zavitsanou
et al. 2002, 2004) and levels and/or activation of which
are altered in adult Nrg1 TM HET mice (Bjarnadottir
et al. 2007; Dean et al. 2008; van den Buuse et al. 2009).
Method
Animals
Male heterozygous Nrg1+/x (Nrg1 TM HET) and wild
type-like control Nrg1+/+ (WT) littermates (Karl et al.
2007) from 14 litters were used. To target adolescence,
the study commenced at post-natal day (PND) 31 (¡2;
Spear, 2004). Standard social interaction (SI) op-
ponents were age-matched male A/JArc mice (Animal
Resources Centre, Australia). Mice were pair-housed
with limited environmental enrichment [certified
polycarbonate mouse igloo (Bioserv, USA) and a
metal ring in the cage lid] under a 12 h light/dark
schedule (lights on 08:30 hours). Food and water were
available ad libitum. Research and animal care proce-
dures were approved by the University of New
South Wales Animal Care and Ethics Committee and
were in accordance with the Australian Code of
Practice for the Care and Use of Animals for Scientific
Purposes.
Drug treatment
THC (THC Pharm GmbH, Germany) was suspended
in a 1:1:18 mixture of ethanol :Tween 801 :saline and
injected at a volume of 10 ml/kg. Mice received 21
consecutive daily i.p. injections of vehicle or THC
(10 mg/kg; n=11–16; Long et al. 2010b).
Behavioural testing
Mice were behaviourally tested as outlined in Table 1.
Devices were cleaned between trials with 70%
ethanol.
Body temperature
Mice were assessed for hypothermia (Compton et al.
1993). Body temperature was measured 5 min before
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and 30 min after injection using a lubricated rectal
thermometer (SDR Clinical Technology, Australia).
Spontaneous locomotor activity
Locomotor activity was measured in an open field
(OF) activity chamber (41r41 cm; Tru-Scan Photo
Beam Activity System; Coulbourn Instruments, USA)
for 10 min. Horizontal (distance travelled) and vertical
activity (rearing) in central and peripheral zones was
measured by the Tru-Scan system and ANY-mazeTM
video tracking software (Stoelting Co., USA). The ratio
of central : total distance travelled (distance ratio) and
time spent in the centre were taken as measures of
anxiety (Denenberg, 1969).
Light–dark test (LD)
Mice were placed into the opening of a dark box insert
(Coulbourn Instruments) in the OF activity chamber
and allowed to explore freely for 10 min. The ratio of
distance travelled in the light compartment to total
distance travelled (distance ratio) and time spent in
the light compartment were taken as measures of
anxiety.
Novel object recognition test (NORT)
NORT apparatus was a grey Perspex arena
(35r35r30 cm). Mice were habituated to the empty
arena for 5 min twice daily for 2 d. The following day,
mice were habituated to the test procedure (i.e. ex-
posure to objects). The next day, mice were placed in
the arena, which contained two identical objects placed
in opposite corners, and allowed to explore freely (test
trial 1). In test trial 2, 60 min later, the chamber con-
tained one copy of these objects (familiar object) and
one novel object, in the same positions as in test trial 1.
Object exploration was scored for 5 min by the behav-
iours nosing (when the mouse directed its nose to an
object at a distance ofj1 cm) and rearing on the object.
Social interaction
SI between rodent pairs is used to measure anxiety-
like behaviours (File & Seth, 2003). Reduction in SI
models aspects of social withdrawal (WD), which also
occurs in schizophrenia (Ellenbroek & Cools, 2000).
Test mice and untreated A/JArc standard opponents
were placed in opposite corners of the NORT arena
and allowed to explore freely for 10 min. Frequency
and duration of the active socio-positive behaviours
general sniffing, anogenital sniffing, allogrooming,
following and climbing over/under were scored
(Boucher et al. 2007a). Distance travelled was meas-
ured by ANY-mazeTM.
Prepulse inhibition
PPI, an operational measure of sensorimotor gating, is
the attenuation of the startle response by a non-
startling stimulus (prepulse) presented before the
startling stimulus (pulse). PPI is impaired in schizo-
phrenia patients (Braff et al. 2001). Startle reactivity
was measured using SR-LAB startle chambers
(San Diego Instruments, USA). Sensitivity of the pie-
zoelectric accelerometer was adjusted for the lower
body weight of the adolescent mice. The PPI test
consisted of 5 min acclimatization to 70 dB back-
ground noise, followed by 105 trials presented in a
pseudorandom order : 5r70 dB trials (background) ;
5r80 dB trials ; 5r100 dB trials ; 15r120 dB trials
(startle) and 15 sets of five trials comprising a prepulse
of 74, 82 or 86 dB presented 32, 64, 128, 256 or 512 ms
(variable inter-stimulus interval) prior to a startling
pulse of 120 dB (PPI response). The inter-trial interval
varied randomly from 10–20 s. Acoustic startle re-
sponse (ASR) was calculated as the mean amplitude to
all startle trials. Percentage PPI (%PPI) was calculated
as [(mean startle response (120 dB) – PPI response)/
mean startle response (120 dB)]r100%. PPI was
averaged across inter-stimulus intervals to produce a
mean %PPI for each prepulse intensity.
Receptor autoradiography
A subset of mice (n=4–5 per factor) were killed after
PPI testing on WD day. Brains were dissected, snap





1 31 Body temperature, catalepsy, OF, LD, PPI
13 43 OF
14 44 NORT habituation trials 1–2
15 45 LD, NORT habituation trial 3
16 46 NORT habituation trials 4–5
17 47 NORT test trials 1–2
19 49 Social interaction
21 51 PPI
23 53 OF, LD, PPI (withdrawal day)
OF, Open field ; LD, light–dark test ; PPI, prepulse inhibition ;
NORT, novel object recognition test.
Mice were injected with either vehicle or D9-tetra-
hydrocannabinol (10 mg/kg body weight) once daily from
test day 1 to day 21 (n=11–16).
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frozen and stored at x80x C. Coronal sections (14 mm)
were cut and thaw-mounted onto slides.
Autoradiographic binding
Ligand binding and quantification was performed as
previously described. For CB1 receptors (CB1Rs) (Deng
et al. 2007), sections were pre-incubated for 30 min in
50 mM Tris-HCl buffer (pH 7.4) containing 5% bovine
serum albumin then incubated for 120 min in the same
buffer containing 10 nM [3H]CP-55, 940 (168 Ci/mmol ;
PerkinElmer, USA) in the presence (non-specific
binding) or absence (total binding) of 10 mM CP 55 940.
After incubation, sections were washed three times in
ice-cold buffer (1r60, 1r180 and 1r5 min), dipped
in distilled water and air dried.
For 5-HT2A receptors (5-HT2AR), sections were pre-
incubated in 170 mM Tris-HCl buffer (pH 7.4) for 15 min
then incubated for 120 min in the same buffer contain-
ing 4 nM [3H]ketanserin (88 Ci/mmol; PerkinElmer) in
the presence (non-specific binding) or absence (total
binding) of 2 mM spiperone (Kang et al. 2009). After in-
cubation, sections were washed in ice-cold buffer
(2r10 min), dipped in distilled water and air dried.
For NMDARs, sections were incubated for 2.5 h
in 30 mM Hepes buffer (pH 7.5) containing 100 mM
glycine, 100 mM glutamate, 1 mM EDTA and 20nM
[3H]MK-801 (17.1 Ci/mmol ; PerkinElmer) in the
presence (non-specific binding) or absence (total
binding) of 20 mM MK-801 (Newell et al. 2007). After
incubation, sections were washed in ice-cold 30 mM
Hepes containing 1 mM EDTA (pH 7.5, 3r20 min),
dipped in distilled water and air dried.
Quantification
Slides were exposed to Kodak BioMaxMR film (Kodak,
USA) for 3 months and developed. Films were analysed
with a computer-assisted image analysis system, Multi-
Analyst, connected to a GS-690 Imaging Densitometer
(Bio-Rad, USA). Brain regions were identified with ref-
erence to amouse brain atlas (Paxinos & Franklin, 2004).
Quantification of binding in each region was performed
by measuring the average density in each region in two
to three adjacent sections for both hemispheres and
comparing the values against an autoradiographic
standard (GE Healthcare, UK) (Kang et al. 2009).
Statistical analysis
Data were analysed with analysis of variance
(ANOVA; between-subjects factors : ‘ treatment’
and ‘genotype’). For OF and PPI, repeated measures
three-way ANOVA was used [within-subjects factor :
‘ interval’ (OF) and ‘prepulse intensity’ (PPI)]. Linear
contrasts identified differences between levels of pre-
pulse intensity. For all analyses, initial ANOVA was
followed by two- or one-way ANOVAs split by
the corresponding factor(s) if appropriate. Main effects
were regarded as statistically significant when p<0.05.
Degrees of freedom, F values and p values (* vs. WT;
# vs. vehicle of corresponding genotype) are pre-
sented. Analysis was performed using SPSS 17.0 IBM,
USA).
Results
At study commencement, WT and Nrg1 TM HET
mice weighed 14.9¡3.0 and 13.7¡3.8 g respectively.
Throughout the study there was no significant differ-
ence in body weight between any groups of mice.
Body temperature
THC reduced body temperature in WT and Nrg1 TM
HET mice [thermic response (DxC) : 0.2¡0.3 (vehicle
WT), x1.1¡0.7 (THC WT), 0.5¡0.7 (vehicle Nrg1 TM
HET), x0.8¡0.4 (THC Nrg1 TM HET) ; two-way
ANOVA for ‘treatment’ : F1,46=5.9, p<0.05].
Locomotor activity
THC decreased locomotion in the OF on day 1 in both
WT and Nrg1 TM HET mice [F1,53=17.8, p<0.001;
Supplementary Table 1 ; Fig. 1a]. This effect was no
longer present on day 13. On WD day, Nrg1 TM HET
mice in both treatment groups showed higher loco-
motor activity than WT controls (F1,51=6.7, p<0.05).
However, only THC-treated Nrg1 TM HETs displayed
significantly lower locomotor activity compared to
vehicle-treated mutants (F1,27=6.6, p<0.05 ; Sup-
plementary Table 1; Fig. 1a).
THC also decreased locomotor activity in the SI test
on day 19 [distance travelled (cm): 2176.7¡91.6 (ve-
hicle WT), 3078.42¡158.0 (vehicle Nrg1 TM HET),
911.8¡163.6 (THCWT); 1328.8¡120.1 (THC Nrg1 TM
HET) ; Supplementary Table 1].
When distance travelled was measured in 5 min
intervals within the OF test, there was an effect of time
on locomotor activity such that distance travelled was
decreased in the second 5 min of the test on all test
days (day 1: F1,52=109.1, p<0.001 ; day 13: F1,51=59.4,
p<0.001 ; WD day: F1,51=17.5, p<0.001; Fig. 1c). THC-
treated mutant mice of both genotypes showed greater
habituation than vehicle-treated mice after acute and
chronic administration (intervalrtreatment interac-
tion, day 1: F1,52=9.3, p<0.01 ; day 13 F1,51=26.7,
p<0.001).
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Exploratory activity
THC reduced rearing in the OF in both genotypes on
days 1 and 13 but not onWDday (e.g. day 1: F1,53=49.4,
p<0.001 ; Supplementary Table 1; Fig. 1b). Exploratory
activity was higher in vehicle-treated Nrg1 TM HET
mice than in their WT counterparts in the OF on day 13
(F1,26=5.1, p<0.05 ; Supplementary Table 1 ; Fig. 1b).
Anxiety
Acute administration of THC on day 1 induced task-
specific anxiogenic-like behaviour in the OF in WT
mice only, which showed more pronounced reduc-
tions in the time spent in the centre (F1,24=11.2,
p<0.01) and the distance ratio (F1,24=9.4, p<0.01)
compared to Nrg1 TM HET mice (Supplementary
Table 1 ; Fig. 2a, c). Chronic THC administration in-
duced anxiogenic-like behaviour in the OF in both
genotypes, as shown by the reduced OF distance ratio
in WT and Nrg1 TM HET mice on day 13 (F1,51=20.2,
p<0.001 ; Supplementary Table 1). In contrast, in the
LD, there were no effects of ‘ treatment’ or ‘genotype’
on anxiety-related parameters (Fig. 2b, d).
Learning and memory
Unexpectedly, exploration times were generally low in
the NORT (<15 s/5-min trial) and object recognition
bias was not highly prevalent in control mice, al-
though the same NORT protocol previously yielded
high recognition scores in our laboratory. Thus, NORT
data are not shown.
Social interaction
There were no effects of THC treatment or genotype on
total time spent in SI (data not shown). However, when
examining individually scored behaviours, THC



































































Fig. 1. Horizontal locomotor and vertical exploratory activity after injection of D9-tetrahydrocannabinol (THC; 10 mg/kg).
(a) Overall distance travelled; (b) rearing ; (c) 5-min interval habituation of distance travelled in the open field (OF) on days 1, 13
and withdrawal (WD) day. Data represent means¡S.E.M. ; n=12–16. WT, Wild-type litter ; HET, heterozygous ; Veh, vehicle.
* p<0.05, ** p<0.01 vs.WT receiving corresponding treatment ; # p<0.05, ## p<0.01, ### p<0.001 vs. vehicle (analysis of variance).
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the frequency of anogenital sniffing (e.g. anogenital
sniffing: F1,50=14.3, p<0.001; Supplementary Table 1;
Fig. 3a, b) and the duration of allogrooming (data not
shown). The effect of THC on the duration of general
sniffing and frequency of anogenital sniffingwas speci-
fic to WT mice and while the frequency of general
sniffingwas reduced by THC in bothWT andNrg1 TM
HET mice, it was significantly higher in THC-treated
Nrg1 TM HET mice (F1,24=5.7, p<0.05) compared to
THC-treatedWTmice (Supplementary Table 1).
ASR and PPI
ASR
Chronic THC decreased the ASR in both WT andNrg1
TM HET mice (F1,51=19.5, p<0.001; Supplementary
Table 2 ; Table 2).
Prepulse inhibition
PPI increased with increasing prepulse intensity on
each test day (Supplementary Table 2 ; Fig. 4a–c).
Acute THC decreased PPI at the 74 dB prepulse
intensity in Nrg1 TM HET mice only (Nrg1 TM HET
74 dB: F1,27=4.8, p<0.05 ; Supplementary Table 2;
Fig. 4a).
CB1, 5-HT2A and NMDAR receptor binding
Figure 5 depicts representative autoradiograms
for [3H]CP 55 940, [3H]ketanserin and [3H]MK-801
binding in WT and Nrg1 TM HET mice. THC
reduced [3H]CP-55 940 CB1R binding in the hippo-
campus (HPC) and ventromedial hypothalamus of
WT and Nrg1 TM HET mice. In the substantia nigra,
CB1R binding was reduced in vehicle-treated Nrg1 TM
HETmice compared to vehicle-treated WT littermates,
while THC reduced CB1R binding in WT mice but in-
creased it inNrg1 TMHETmice [treatmentrgenotype
interaction : F1,13=28.2, p<0.001; Supplementary
Table 3; Fig. 6a]. There was a trend towards a re-
duction in CB1R binding by THC in the external globus
pallidus in both genotypes (p=0.06).






























































Fig. 2. Anxiety-related measures after injection of D9-tetrahydrocannabinol (THC) (10 mg/kg). (a) Time spent in the central
area of the open field (OF) on days 1, 13 andwithdrawal (WD) day ; (b) time spent in the light compartment of the light–dark (LD)
on days 1, 15 and WD; (c), distance ratio (OF) ; (d) distance ratio (LD). Data represent means¡S.E.M. ; n=11–16. WT, wild-type
litter ; HET, heterozygous ; Veh, vehicle. ## p<0.01 vs. vehicle (analysis of variance).
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[3H]Ketanserin 5-HT2AR binding was also genotype
and treatment dependent. Specifically, vehicle-treated
Nrg1 TMHET mice showed reduced 5-HT2AR binding
in the agranular insular and cingulate cortices but
increased binding in the caudate putamen compared
to WT controls. THC reduced 5-HT2A binding in the
anterior insula, cingulate cortex and ventral pallidum
and increased binding in the caudate putamen of
WT mice, but in Nrg1 TM HET mice THC increased
5-HT2AR binding only in the anterior insula (F1,6=39.8,
p<0.001 ; Supplementary Table 3 ; Fig. 6b).
The effects of THC on [3H]MK-801 NMDAR bind-
ing were restricted to mutant mice, such that THC
increased binding in the auditory cortex, cingulate
cortex and hippocampus ofNrg1 TMHET, but not WT
mice (e.g. Nrg1 TM HET in HPC: F1,7=15.0, p<0.01 ;
Supplementary Table 3 ; Fig. 6c).
Discussion
This study describes novel effects of adolescent THC
on behaviour and receptor binding in a mouse model
for the schizophrenia candidate gene NRG1. THC
produced acute and chronic hypolocomotor and
hypoexploratory responses in both Nrg1 TM HET and
WT mice, but only mutant mice showed residual hy-
polocomotion after THCWD. In contrast, mutant mice
were less susceptible to other effects of THC, such as
acute anxiogenic effects and reduction in investigative
sniffing during SI elicited by repeated THC exposure.
Repeated adolescent THC notably promoted differen-
tial effects on CB1R and 5-HT2AR density in the sub-
stantia nigra and insular cortex respectively, such
that THC decreased binding density in WT but in-
creased it in Nrg1 TM HET mice. While repeated
adolescent THC also affected 5-HT2AR density in WT
mice in the ventral pallidum, caudate putamen and
cingulate cortex, no such effects were observed in
Nrg1 TM HET mice. Interestingly, the opposite pro-
file was evident for NMDAR binding: repeated
adolescent THC increased binding density in the
hippocampus and auditory and cingulate cortices in
mutants only.
Behavioural effects of Nrg1 genotype and THC
treatment
Baseline hyperactivity in Nrg1 TM HET mice
emerged at an earlier age (PND 49–53) in this study
than previously reported (Karl et al. 2007). As the Nrg1
TM HET phenotype is sensitive to environmental
modification (Karl et al. 2007), effects of the individu-
ally ventilated cage housing used in the present study
and conventional housing used previously as well as



















































Fig. 3. Measures of social interaction after injection of D9-tetrahydrocannabinol (THC) (10 mg/kg) on day 19. (a) Frequency of
general sniffing; (b) anogenital sniffing. Data represent means¡S.E.M. ; n=12–14. WT, wild-type litter ; HET, heterozygous ; Veh,
vehicle. * p<0.05 vs. WT; ## p<0.01, ### p<0.001 vs. vehicle (analysis of variance).
Table 2. Acoustic startle response
Day
WT Nrg1 TM HET
Vehicle THC 10 Vehicle THC 10
1 51.7¡5.8 45.6¡5.0 45.3¡3.5 34.0¡3.8
21 73.2¡5.7 46.8¡4.3## 57.0¡6.5 39.5¡2.4#
WD 69.0¡6.2 87.2¡11.9 52.7¡6.0 60.5¡7.0
Nrg1 TM HET, heterozygous transmembrane domain Nrg1
mutant ; WT, wild-type-like littermate control ;
WD, withdrawal day.
Chronic D9-tetrahydrocannabinol (THC; 10 mg/kg) reduces
the startle response (arbitrary units) to a 120 dB acoustic
stimulus.
Data represent means (¡S.E.M.) ; n=12–15.
# p<0.05 ; ## p<0.01 (vs. vehicle).
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the adolescent treatment procedure (i.e. stress of daily
i.p. injections) might have contributed to the earlier
phenotype onset (Kallnik et al. 2007). Repeated OF
testing is unlikely to have contributed to the earlier
onset as we have previously shown that locomotor
activity is not altered by repeated exposure of Nrg1
mutant mice to the OF paradigm (Boucher et al. 2011;
Karl et al. 2007).
Acute THC elicited the typical cannabinoid effects
of hypothermia and hypolocomotion in WT mice,
similarly to our previous studies (Boucher et al. 2007a ;
Long et al. 2010b). These effects, observed at around
PND 31, may represent one of the earliest manifes-
tations of activation of CB1Rs, which are suggested to
be functionally immature until around PND 23, i.e.
after weaning (Fride & Mechoulam, 1996). THC in-
duced hypolocomotion in adolescents of both geno-
types, which contrasts with the heightened sus-
ceptibility to THC-induced hypolocomotion of adult
Nrg1 TMHET mice (Boucher et al. 2007a). It is possible
that using a lower, less sedative dose of THC in the
present study, such as 1 mg/kg, may have unmasked
some subtle differences in locomotor effects of THC
between genotypes at this younger age.
Adolescent mice developed an overall tolerance to
THC-induced hypolocomotion in the OF after chronic
exposure. While tolerance to cannabinoid agonist-
induced hypolocomotion is common (Boucher et al.
2011; Howlett et al. 2004), adolescent rats have
been reported to be less susceptible than adults to
the development of tolerance (Wiley et al. 2007).
Interestingly, in THC-treated mice of both genotypes,
hypolocomotor tolerance was evident only in the
first half of the 10 min OF test on day 13, suggesting
that the rate of tolerance to some THC effects may
interact with its effects on habituation to the test
environment. On the other hand, residual hypolo-
comotion was present in THC-treated Nrg1 TM
HET, but not WT mice in the OF and LD at WD.
One possible interpretation for this phenomenon is
that THC induced selective neurobiological alterations
in Nrg1 TM HET mice, which diminished the emerg-
ence of the typical hyperactive phenotype of these
mice.
There were no baseline genotype differences in
generalized anxiety-like behaviour in the adolescent
mice, confirming the age-dependency of phenotypic
features of this Nrg1 mutant mouse model, since a
task-specific, anxiety-related phenotype has been
observed in adult Nrg1 TM HET mice (Karl et al.
2007). Acute THC induced anxiety-like effects task-
specifically in the OF, predominantly in WT mice,
whereas chronic effects were detectable in all mice.
The data suggest that adolescent WT and Nrg1 TM
HET mice have similar responses to chronic, but
not acute, effects of THC on anxiety measures and that
the effects of repeated adolescent THC exposure are
not long lasting. This also appears to be an age-
dependent phenomenon, as adult Nrg1 mutants ex-
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Fig. 4. Sensorimotor gating after injection of D9-
tetrahydrocannabinol (10 mg/kg). (a–c) % Prepulse
inhibition (PPI) on days 1, 21 and withdrawal day.
Data represent means¡S.E.M. ; n=12–15. WT, wild-type litter ;
HET, heterozygous ; Veh, vehicle. # p<0.05 vs. vehicle
(analysis of variance).
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Interestingly, adolescent Nrg1 TM HET mice were
resistant to THC-induced suppression of investigative
social behaviours. There were no baseline differences
between vehicle-treated mutant and WT mice in the SI
test, which intends to model both social anxiety and
social WD. While acute THC reduced total SI to a
similar extent in adult Nrg1 TM HET and WT mice
(Boucher et al. 2007a), we now show that THC selec-
tively reduced general sniffing and anogenital sniffing
in adolescent WT mice. This selective reduction in in-
vestigative social behaviour cannot be explained by a
locomotor suppressant effect of THC, since THC re-
duced locomotion to the same extent in both WT and
Nrg1 TM HET mice. It is possible that adolescent Nrg1
TM HET mice undergo differential neurobehavioural
adaptations to repeated THC that render them less
susceptible to reductions in social behaviour induced
by the drug – an effect worthy of consideration in light
of the purported relief from negative symptoms
experienced by cannabis users with schizophrenia
(Smit et al. 2004).
There were no baseline genotype differences in
startle response and PPI. Importantly, the PPI deficit of
Nrg1 TM HET mice initially reported (Stefansson et al.
2002) has not been replicated reliably (Boucher et al.
2007a ; van den Buuse et al. 2009; but also see
Boucher et al. 2011; Karl et al. 2011). Acute THC treat-
ment selectively reduced PPI at the lowest prepulse
intensity in Nrg1 TM HET mice but did not alter the
startle response, while chronic THC reduced the star-
tle response in both genotypes but did not alter PPI
during treatment or WD. These data suggest that THC
has differential acute effects on sensorimotor gating in
adult and adolescent Nrg1 TM HET mice, since we
have previously found that a single THC exposure












Fig. 5. Representative autoradiograms showing [3H]CP 55 940, [3H]ketanserin and [3H]MK-801 binding in specific brain regions
in wild-type litter and heterozygous transmembrane domain Nrg1 mutant (Nrg1 TM HET) mice. PrL, Prelimbic cortex ; AI,
agranular insular cortex ; Cg, cingulate cortex ; CPu, caudate putamen; VP, ventral pallidum; GPe, external globus pallidus ; Au,
auditory cortex ; HPC, hippocampus ; VMH, ventromedial hypothalamus ; SN, substantia nigra.
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effect was observed in WT mice (Boucher et al. 2007a).
Furthermore, repeated THC exposure had no effect on
PPI in adolescent WT and Nrg1 TM HET mice, simi-
larly to our recent findings in adult mutants after re-
peated exposure to a synthetic cannabinoid agonist
(Boucher et al. 2011).
Effects of Nrg1 genotype and THC treatment on
autoradiographic receptor binding
We report for the first time a decrease in CB1R density
in the substantia nigra of adolescent Nrg1 TM HET
mice. Since the binding ligand we used is a CB1R
agonist, it is possible that this finding reflects altered
binding site affinity rather than overall receptor num-
ber. Nevertheless, we note with interest that using the
same radioligand ([3H]CP 55 940), CB1R binding was
modestly increased in the substantia nigra in adult
Nrg1 TM HET mice (Newell et al. unpublished ob-
servations), suggesting that the developmental trajec-
tory of CB1R expression between adolescent and adult
mice differs between Nrg1 TM HET and WT mice.
Within the basal ganglia, CB1R mRNA is synthesized
in striatal medium spiny neurons and the receptor
protein is transported to terminals projecting to the
substantia nigra via the direct pathway and the exter-
nal globus pallidus via the indirect pathway (Julian
et al. 2003; van der Stelt & di Marzo, 2003). These
pathways facilitate and inhibit movement, respect-
ively. The reduced CB1R binding in vehicle-treated
adolescent mutant mice appears specific to the direct
pathway, since CB1R binding was not altered in the
external globus pallidus. Combined with the obser-
vation that mRNA encoding ErbB4 receptors for
NRG1 is localized on dopaminergic neurons in the
substantia nigra (Abe et al. 2009), it is possible to
speculate that hyperactivity in Nrg1 mutant mice in-
volves altered nigral dopaminergic neurotransmis-
sion, possibly related to reduced CB1R availability in
the direct pathway. We also report for the first time
genotype differences in the effects of repeated ado-
lescent THC on CB1R binding in the substantia nigra,
such that it reduced CB1R binding in WT mice (con-
sistent with prior research; Romero et al. 1997) but in-
creased binding in Nrg1 TM HETs. Combined with a
trend towards reduced CB1R binding in the external
globus pallidus of both WT and mutant mice treated
with THC, this suggests an involvement of both direct
and indirect pathway CB1Rs in the locomotor effects of
chronic THC in WT mice. The increased CB1R binding
in the substantia nigra of THC-treated Nrg1 TM HET
mice may represent a maladaptive or compensatory
response underlying the persistent reduction in loco-
motor activity after THC WD in mutant mice.
5-HT2AR binding was reduced in the anterior insu-
lar and cingulate cortices and increased in the caudate
putamen of drug-free, adolescent Nrg1 TM HET mice.
This is consistent with reduced 5-HT2AR density in
prefrontal and other cortical regions in schizophrenia
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Fig. 6. Autoradiographic binding of (a) [3H]CP-55 940, (b)
[3H]ketanserin and (c) [3H]MK-801 on withdrawal day. Data
represent mean binding density nCi/mg tissue (¡S.E.M.) ;
n=4–5. WT, wild-type-like littermate control ;
HET, heterozygous ; Veh, vehicle ; CPu, caudate putamen;
HPC, hippocampus ; VMH, ventromedial hypothalamus ; SN,
substantia nigra ; GPe, external globus pallidus ; AI, agranular
insular cortex ; VP, ventral pallidum; PrL, prelimbic cortex ;
Cg, cingulate cortex ; ACo, auditory cortex ; PMCo,
posteromedial cortical amygdaloid nucleus. * p<0.05,
** p<0.01 vs.WT; # p<0.05, ## p<0.01, ### p<0.001 vs. vehicle
(analysis of variance).
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2000). Given that our data are from mice in mid-ado-
lescence, the findings are particularly relevant to ob-
servations in the early stages of schizophrenia in
humans, such as reduction in cortical 5-HT2ARs in in-
dividuals at high risk for schizophrenia (Hurlemann et
al. 2008) and in first-episode patients (Rasmussen et al.
2010), and increased subcortical 5-HT2ARs (Erritzoe et
al. 2008) in first-episode patients. While this suggests
that changes in 5-HT2ARs may be an early manifes-
tation of schizophrenia neuropathophysiology, it is
possible that genetic influences such as Nrg1 mutation
may alter the development of the expression of this
receptor, since we have previously observed a global
increase in 5-HT2ARs in adult Nrg1 TM HET mice
(Dean et al. 2008). The effects of THC on 5-HT2ARs,
similar to CB1Rs, also appear to be genotype-specific,
such that THC reduced binding in the agranular
insula and ventral pallidum in WT mice but increased
or did not change it in mutants. Overall, our results
suggest that Nrg1 modulates 5-HT2AR binding den-
sity in brain regions relevant to schizophrenia and
social anxiety (Furmark, 2009 ; Vertes, 2006 ; Wylie &
Tregellas, 2010), which may subserve the differential
patterns in THC effects on social anxiety in the present
study.
We observed no baseline genotype differences in
NMDAR binding. This is in line with a previous report
of hypophosphorylation, but no change in total pro-
tein levels, of the NMDARNR2B subunit in adultNrg1
TM HET mice (Bjarnadottir et al. 2007). Meanwhile,
NMDAR binding density was selectively increased
in the hippocampus and auditory and cingulate cor-
tices of THC-treated mutant mice. This may represent
an adaptation to THC-induced changes in endo-
cannabinoid control of synaptic transmission (Bodor
et al. 2005; Brown et al. 2003; Hoffman et al. 2010). Since
NMDAR antagonists generally induce hyperactivity,
increased NMDAR density may also underlie the
persistent hypolocomotion after THC WD in mutant
mice.
Here, we add to the Nrg1 mutant mouse model
literature by reporting adolescence-specific and
genotype-dependent differences in the neurobeha-
vioural response of these mice to THC. We hypoth-
esized that adolescent Nrg1 TM HET mice would be
more susceptible to the hypolocomotor, hyposocial
and anxiogenic effects of THC. However, we found no
difference in the sensitivity of mutant mice to loco-
motor reduction by THC and, in fact, mutants were
less susceptible to THC-induced reduction in social
behaviour and to induction of anxiety-like behaviour
by acute THC. Furthermore, the changes in CB1, 5-
HT2A and NMDAR receptors in adolescent mutants
that we observe are different to those previously found
in adult mice, supporting the implications of our be-
havioural data that there are developmental differ-
ences in both the baseline phenotype of these mice and
in their behavioural and neurochemical response to
chronic cannabinoid agonist exposure. Overall, these
findings are consistent with evidence for differential
effects of THC between adolescents and adults and
between ‘vulnerable’ (i.e. genetically modified) and
‘healthy’ brains.
Note
Supplementary material accompanies this paper on
the Journal’s website (http://journals.cambridge.org/
pnp).
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